Factor VIII deficiency plasma protectants and their applications
By using a specific combination of protectants to stabilize factor VIII-deficient plasma, the compatibility and stability issues of existing kits have been resolved, enabling more precise and cost-effective detection of coagulation factors.
Patent Information
- Application Number
- CN202310392194.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-13
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-04-13
AI Technical Summary
Existing coagulation factor VIII deficiency plasma kits have limited compatibility, are expensive, have poor stability, and are easily affected by the external environment, resulting in high testing costs and inaccuracies.
HEPES buffer, Tris buffer, phosphate buffer, magnesium sulfate, polyvinylpyrrolidone, histidine, glycine, sucrose, trehalose, sodium azide, ciprofloxacin, thimerosal, gentamicin, and Proclin-300 were used as protectants to form a lyophilization protectant, which protected factor VIII from plasma-induced activity.
It improves the stability and precision of factor VIII-deficient plasma, ensuring the accuracy and consistency of test results, is applicable to a variety of coagulation analyzers, and reduces testing costs.
Smart Images

Figure BDA0004176187470000061 
Figure BDA0004176187470000071 
Figure BDA0004176187470000081
Abstract
Description
Technical Field
[0001] This invention relates to the field of in vitro diagnostic reagent technology, specifically to a factor VIII deficiency plasma protectant and its application. Background Technology
[0002] Coagulation factor VIII (FVIII) is a globulin involved in the blood clotting process. The liver and vascular endothelium are the main sites of FVIII synthesis. FVIII is present in plasma, at a concentration of approximately 0.1 mg / L, the lowest among all plasma coagulation factors. FVIII functions as a cofactor of FIXa, participating in the activation of FX by FIXa. However, FVIII in plasma exists in a heterodimer form and has no intrinsic activity; it must be activated by thrombin or FXa enzymes to be converted into the active cofactor FVIIIa. 2+ Under certain conditions, FⅧa and FⅨa form a complex (FⅧa-FⅨa) on the phospholipid surface, which can greatly increase the activation rate of FⅨa for FⅩ.
[0003] Elevated FVIII activity levels in plasma are mainly seen in hypercoagulable states and thrombotic diseases, especially venous thrombotic disorders such as deep vein thrombosis, pulmonary embolism, nephrotic syndrome, oral contraceptive use, preeclampsia, malignant tumors, and liver disease. Decreased FVIII activity levels in plasma are commonly seen in hemophilia, the earliest discovered and most common hereditary bleeding disorder caused by a deficiency or defect in coagulation factor VIII. Therefore, detecting coagulation factor VIII activity is of significant clinical importance for the diagnosis and treatment of hemophilia.
[0004] The main methods for determining coagulation factor VIII are the coagulation method and the chromogenic substrate method. Commercially available kits for determining coagulation factor VIII using the coagulation method fall into two categories. One is the two-phase detection method, which is based on detecting the ability of factor VIII as a cofactor to form a complex with factor IXa to activate factor X. The activity of factor VIII can be calculated by detecting the amount of factor Xa generated. This experiment is performed in two steps: First, the sample is incubated with a reagent solution containing phospholipids, calcium ions, factor IXa, and factor X to generate factor Xa; second, excess prothrombin and fibrinogen are added, and the time for fibrin clot formation is measured. The measured coagulation time can be used to obtain the coagulation factor activity by comparing it with a calibration curve of known coagulation factor activity or by substituting it into a regression equation. The other method is the one-phase detection method, which is based on detecting the ability of the sample to correct for the prolongation of coagulation time (activated partial thromboplastin time, APTT) caused by factor-deficient plasma. This is currently the most commonly used method for determining coagulation factor activity. The diluted test plasma was mixed with factor VIII-deficient plasma and then subjected to APTT testing. The test results were negatively correlated with the activity of coagulation factor VIII in the test plasma. A calibration curve was established by serially diluting plasma with known coagulation factor VIII activity and mixing it with factor VIII-deficient plasma before performing APTT testing. This method can determine the activity of coagulation factor VIII in the test plasma, offering high sensitivity and ease of operation.
[0005] Currently, there are several kits on the market for determining factor VIII activity, but most of them are only compatible with their own coagulation analyzers, which limits their applicability. Moreover, similar products on the domestic market are all manufactured abroad, which are expensive, have high testing costs, long delivery times, and are susceptible to external environmental factors, leading to coagulation factor inactivation and thus reducing the stability of the kits. Summary of the Invention
[0006] In view of this, the technical problem to be solved by the present invention is to provide a factor VIII deficiency plasma protectant and its application. The factor VIII deficiency plasma protectant provided by the present invention can effectively protect the activity of factor VIII deficiency plasma before and after freeze-drying. Its preparation method is simple, inexpensive, highly precise and stable.
[0007] This invention provides protective agents, including buffers, lyophilization protectants, and preservatives, wherein,
[0008] The buffer includes at least one of HEPES buffer, Tris buffer, and phosphate buffer.
[0009] The freeze-drying protectant includes at least one of magnesium sulfate, polyvinylpyrrolidone, histidine, glycine, sucrose, and trehalose;
[0010] The preservatives include at least one of sodium azide, ciprofloxacin, thimerosal, gentamicin, and Proclin-300.
[0011] Compared to the selection of other components, the components in the protective agent provided by the present invention work together to provide a more stable freeze-drying system for the preparation of freeze-dried plasma. This system can protect the activity of various coagulation factors and plasminogen in the plasma to the greatest extent, effectively stabilize the plasma, and thus obtain more accurate technical results.
[0012] In some specific embodiments, the lyophilization protectant is magnesium sulfate, polyvinylpyrrolidone, histidine, and trehalose. Compared to other components, the lyophilization protectant contains both histidine and trehalose, which effectively reduces the impact of the lyophilization process on active factors in plasma; the presence of magnesium sulfate and polyvinylpyrrolidone effectively improves plasma stability. The four components—histidine, trehalose, magnesium sulfate, and polyvinylpyrrolidone—work together as a lyophilization protectant, exhibiting close synergy and simultaneously protecting the activity and stability of various coagulation factors and plasminogen in plasma, thereby achieving more accurate technical results.
[0013] Preferably, the buffer is HEPES buffer solution.
[0014] Preferably, the preservative is ciprofloxacin.
[0015] Compared to other components, the components of the above protective agents work closely together and have strong compatibility, which can more effectively assist in the preparation of freeze-dried plasma, thereby obtaining more accurate technical results.
[0016] Preferably, the protective agent is composed of water, 10-80 mM HEPES buffer, 1-10 mM magnesium sulfate, 0.1-1 g / L polyvinylpyrrolidone, 10-50 g / L histidine, 10-50 g / L trehalose and 0.001%-0.005% (w / v) ciprofloxacin, and the pH value of the protective agent is 7.5.
[0017] A comparative experiment was conducted between the freeze-dried plasma prepared using the above-mentioned components and concentration range of the protective agent and commercially available products. The precision of the normal range quality control plasma and the pathological range quality control plasma was tested. The results showed that the coefficient of variation (CV) of the normal range quality control plasma and the pathological range quality control plasma provided by the present invention was smaller than that of the commercially available products, indicating better precision. The relative deviation of the detection activity of the plasma before and after freeze-drying was small, and the freeze-thaw, reconstitution and long-term stability were high, thus obtaining more accurate technical results.
[0018] More preferably, the protective agent is composed of water, 50 mM HEPES buffer, 5 mM magnesium sulfate, 0.5 g / L polyvinylpyrrolidone, 25 g / L histidine, 25 g / L trehalose, and 0.002% (w / v) ciprofloxacin, and the pH value of the protective agent is 7.5.
[0019] Experiments show that at this concentration, the freeze-dried plasma prepared with the protective agent has the best effect, the best precision, the smallest relative deviation in the detection activity of the plasma before and after freeze-drying, and the highest stability during freeze-thaw and reconstitution, thus achieving more accurate technical results.
[0020] The present invention also provides the use of the protective agent in the preparation of coagulation factor-deficient plasma or in a kit containing coagulation factor-deficient plasma.
[0021] Preferably, the coagulation factor-deficient plasma includes factor VIII-deficient plasma. In some specific embodiments, the factor VIII-deficient plasma is human factor VIII-deficient plasma.
[0022] The present invention provides a kit containing factor VIII deficient plasma or factor VIII deficient plasma, comprising human factor VIII deficient plasma and the protective agent.
[0023] This invention provides the application of the aforementioned factor VIII deficient plasma in the preparation of coagulation factor activity detection reagents or kits.
[0024] This invention provides a method for detecting factor VIII activity in human plasma using a coagulation factor activity assay kit, the specific steps of which are as follows:
[0025] (1) Dilute the plasma sample with buffer at a ratio of 1:10, pipette the solution into a test tube, and preheat at 37°C;
[0026] (2) Factor VIII deficiency plasma and diluted plasma sample were mixed at a volume ratio of 1:1, mixed at 37°C and incubated for 2 minutes;
[0027] (3) Add APTT reagent and mix with the diluted plasma sample at a volume ratio of 1:1, mix at 37°C and incubate for 2 minutes;
[0028] (4) Add 0.025 mol / L CaCl2 reagent and mix it with the diluted plasma sample at a volume ratio of 1:1, react at 37°C for 2 minutes, and measure the coagulation time;
[0029] (5) The activity of factor VIII in the plasma sample was calculated based on the known standard curve.
[0030] This invention provides a protective agent comprising a buffer, a lyophilization protectant, and a preservative, including factor VIII-deficient plasma and the protective agent, and the application of factor VIII-deficient plasma in the preparation of coagulation factor activity assay reagents or kits. Compared with existing technologies, the protective agent provided by this invention can effectively ensure the stability and activity of proteins in factor VIII-deficient plasma, resulting in higher precision and further improving the performance of products containing factor VIII-deficient plasma. The protective agent of this invention uses four components—histidine, trehalose, magnesium sulfate, and polyvinylpyrrolidone—as a lyophilization protectant. Histidine and trehalose effectively reduce the impact of the lyophilization process on active factors in the plasma, while magnesium sulfate and polyvinylpyrrolidone effectively improve plasma stability, including freeze-thaw stability, reconstitution stability, and long-term stability. The factor VIII-deficient plasma provided by this invention maintains essentially the same activity after 39 months of storage. The factor VIII-deficient plasma provided by this invention is suitable for most commercially available fully automated coagulation analyzers. Attached Figure Description
[0031] Figure 1 This paper presents a correlation analysis of the test results of the reagent kit of the present invention and similar reagent kits from Siemens on the CS5100 fully automated blood coagulation analyzer.
[0032] Figure 2 This paper presents a correlation analysis of the test results of the reagent kit of the present invention and similar reagent kits from Stago on the STA-R Evolution fully automated blood coagulation analyzer;
[0033] Figure 3 This paper presents a correlation analysis of the test results of the reagent kit of the present invention and similar IL kits on the ACL TOP750 fully automated blood coagulation analyzer. Detailed Implementation
[0034] This invention provides a factor VIII deficiency plasma protectant and its application. Those skilled in the art can refer to the content of this document and appropriately modify the process parameters to achieve the desired result. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in this invention. The methods and applications of this invention have been described through preferred embodiments. Those skilled in the art can clearly modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit, and scope of this invention to implement and apply the technology of this invention.
[0035] This invention provides protective agents, including buffers, lyophilization protectants, and preservatives, wherein,
[0036] The buffer includes at least one of HEPES buffer, Tris buffer, and phosphate buffer.
[0037] The freeze-drying protectant includes at least one of magnesium sulfate, polyvinylpyrrolidone, histidine, glycine, sucrose, and trehalose;
[0038] The preservatives include at least one of sodium azide, ciprofloxacin, thimerosal, gentamicin, and Proclin-300.
[0039] The test materials used in this invention are all common commercially available products. The invention is further illustrated below with reference to embodiments:
[0040] Example 1: Preparation of the reagent kit and control experimental group of the present invention
[0041] (1) The reagent kit of the present invention
[0042] The plasma used in this invention is human plasma, supplied by Biomex GmbH, Germany. Buffers, preservatives, lyophilization protectants, etc., are added to the plasma and mixed thoroughly to a pH of 7.5. The reagent kit formulation of this invention is shown in Table 1.
[0043] Table 1. Plasma formulation for factor VIII deficiency (experimental group)
[0044] Components content HEPES 50mM Magnesium sulfate 5mM Polyvinylpyrrolidone 0.5g / L Histidine 25g / L Trehalose 25g / L Ciprofloxacin 0.002%
[0045] (2) Control group
[0046] The control group with factor VIII deficiency plasma settings are shown in Table 2.
[0047] Table 2. Plasma formulation for factor VIII deficiency (control group)
[0048]
[0049] Example 2 Precision Detection
[0050] The factor VIII deficient plasma samples from the experimental group and control groups 1-10 of this invention were used to test Siemens original quality control plasma with normal range set values (Control Plasma N) and pathological range set values (Control Plasma P). The tests were repeated 20 times, and the coefficient of variation (CV) was calculated. The results are shown in Tables 3-6. Tables 3 and 5 contain the precision test results of the experimental group and control groups 1-10 for the normal range set value control plasma (Control Plasma N), while Tables 4 and 6 contain the precision test results of the experimental group and control groups 1-10 for the pathological range set value control plasma (Control Plasma P). The results in Tables 3-4 show that the coefficient of variation (CV) value of the experimental group is significantly lower than that of the control groups 1-4, indicating that the factor VIII assay kit (coagulation method) of this invention has significantly better precision than the control groups 1-4. Therefore, the combination of magnesium sulfate, polyvinylpyrrolidone, histidine, and trehalose is superior to any combination of three of them. The combination of magnesium sulfate, polyvinylpyrrolidone, histidine, and trehalose found in factor VIII-deficient plasma in the kit of this invention results in higher precision. Meanwhile, the results in Tables 3-4 (experimental and control groups 5-6) show that replacing histidine with other amino acids and trehalose with other sugars still achieves the function of this invention, but the effect is not as good as with histidine and trehalose alone. The results in Tables 3-4 (experimental and control groups 7-10) show that the coefficient of variation (CV) is less than 5% when the concentrations of magnesium sulfate (1-10 mM), polyvinylpyrrolidone (0.1-1 g / L), histidine (10-50 g / L), and trehalose (10-50 g / L). Specifically, the coefficient of variation (CV) is lowest and the precision is highest when the concentration of magnesium sulfate is preferably 5 mM, the concentration of polyvinylpyrrolidone is preferably 0.5 g / L, the concentration of histidine is preferably 25 g / L, and the concentration of trehalose is preferably 25 g / L.
[0051] Table 3. Precision test results of Control Plasma N
[0052] Serial Number Experimental group (%) Control group 1 (%) Control group 2 (%) Control group 3% Control group: 4% 1 93.5 104.6 94.1 99.3 93.5 2 94.5 109.7 93.6 92.6 95.6 3 94.6 102.6 94.8 94.6 97.8 4 94.2 105.6 96.1 97.8 92.4 5 93.6 99.2 96.7 95.6 88.6 6 93.4 98.7 95.7 98.4 95.3 7 94.2 96.3 98.9 94.6 92.3 8 94.5 98.2 95.3 92.3 96.5 9 93.5 97.6 93.6 91.6 93.7 10 93.8 94.5 92.4 91.9 98.5 11 94.1 96.5 92.6 90.9 94.2 12 93.4 97.8 92.8 90.8 91.5 13 93.5 98.2 93.6 91.8 95.8 14 93.8 94.3 93.7 94.6 98.4 15 93.2 93.2 91.2 96.2 93.2 16 93.1 89.7 92.8 96.5 97.1 17 94.5 86.5 91.6 97.1 98.6 18 94.1 88.3 96.7 97.6 97.5 19 94.5 86.7 92.3 98.8 94.6 20 93.6 87.1 93.5 99.1 92.1 mean 93.9 96.3 94.1 95.1 94.9 CV 0.49% 6.73% 2.08% 3.08% 2.88%
[0053] Table 4. Precision test results of Control Plasma N (control group 5-10)
[0054]
[0055]
[0056] Table 5 Precision test results of Control Plasma P
[0057] Serial Number Experimental group (%) Control group 1 (%) Control group 2 (%) Control group 3% Control group: 4% 1 29.3 29.7 28.6 29.7 28.1 2 29.3 29.3 27.3 28.6 29.5 3 29.1 29.3 27.3 28.9 29.1 4 28.6 28.5 27.2 29.1 28.6 5 28.9 28.3 26.5 29.3 28.7 6 29.2 27.4 26.7 29.6 26.3 7 29.1 28.2 28.3 28.1 26.5 8 28.6 27.1 28.2 27.6 27.5 9 28.5 27.6 27.6 27.9 27.9 10 28.9 26.4 26.8 27.3 28.6 11 29.3 28.4 26.3 27.6 28.9 12 28.6 29.6 27.3 26.9 28.6 13 28.6 30.1 28.3 26.8 28.1 14 28.9 31.3 28.9 26.4 26.9 15 28.9 31.2 29.6 26.1 26.5 16 29.1 32.3 29.4 25.6 26.6 17 29.3 32.6 29.2 27.6 26.1 18 28.6 32.7 28.6 27.3 26.7 19 28.9 32.9 28.1 26.8 26.8 20 29.1 33.1 27.6 24.6 26.2 mean 28.9 29.8 27.9 27.6 27.6 CV 0.96% 7.13% 3.51% 4.93% 4.04%
[0058] Table 6. Precision test results of Control Plasma P (control group 5-10)
[0059]
[0060] Example 3: Study on the protective effect of freeze-drying
[0061] The factor VIII-deficient plasma from the kit of this invention (experimental group) and control groups 3-4 were lyophilized. Before and after lyophilization, the normal range control plasma (Control Plasma N) and pathological range control plasma (Control Plasma P) from Siemens original quality control materials were measured, with measurements repeated three times. The mean and relative deviation of the test results before and after lyophilization were calculated. Table 7 shows that the relative deviation of the experimental group's test values for the quality control materials before and after lyophilization was significantly lower than that of the control group 3-4, indicating that the presence of both histidine and trehalose in factor VIII-deficient plasma can effectively reduce the impact of the lyophilization process on factor VIII-deficient plasma.
[0062] Table 7. Test results before and after freeze-drying
[0063]
[0064] Example 4 Reconstitution Stability
[0065] Factor VIII deficiency plasma from the experimental and control groups 1-2 was freeze-dried. The freeze-dried product was reconstituted with 1 mL of distilled water, and simultaneously, a commercially available kit was reconstituted to the indicated volume and stored at +18–+25°C. Tests were performed every 2 hours after reconstitution. Each test used Siemens original quality control plasma within the normal range (Control Plasma N) and within the pathological range (Control Plasma P), repeated three times, and the mean value was calculated. Linear regression was performed on the results, and a two-tailed t-test was conducted to assess the significance of the slope b compared to 0. The results are shown in Table 8. As shown in Table 8, α = 0.05, ν = 9, and tα(ν) = 2.262. The p-values for the activity assay results of the kit of this invention are all greater than 0.05, which fully demonstrates that the kit of this invention is more stable than commercially available kits and can further extend the shelf life of factor VIII-deficient plasma. The activity detection values of the lyophilized product of the kit of this invention remain essentially unchanged after being placed at +18 to +25°C for 20 hours. The assay results of the kit of this invention and control groups 1-2 fully demonstrate that the simultaneous presence of magnesium sulfate and polyvinylpyrrolidone in factor VIII-deficient plasma can effectively improve the stability of enzyme activity during the reconstitution process of factor VIII-deficient plasma.
[0066] Table 8 Results of Reconstitution Stability Test
[0067]
[0068]
[0069] Example 5 Freeze-thaw stability
[0070] Plasma samples from the experimental group (factor VIII deficiency) and control groups 1-2 were freeze-dried. The freeze-dried samples were reconstituted with 1 mL of distilled water, and simultaneously, a commercially available reagent kit was reconstituted to the indicated volume. After mixing, both were stored at -20°C. The frozen plasma was thawed the next day, and tests were performed every hour after thawing. Each test used Siemens original quality control plasma with normal range settings (Control Plasma N) and pathological range settings (Control Plasma P), repeated three times, and the mean value was calculated. Linear regression was performed on the results, and a two-tailed t-test was conducted to assess the significance of the slope b versus 0. The results are shown in Table 9. As shown in Table 9, α = 0.05, ν = 9, and tα(ν) = 2.262. The p-values for the activity assay results of the kit of this invention are all greater than 0.05, which fully demonstrates that the kit of this invention is more stable than commercially available kits. The activity detection values of the lyophilized product of the kit of this invention remain essentially unchanged after being stored at +18 to +25°C for 10 hours following freeze-thaw cycles. The assay results of the kit of this invention and control groups 1-2 fully demonstrate that the presence of both magnesium sulfate and polyvinylpyrrolidone in factor VIII-deficient plasma can effectively improve the stability of enzyme activity during the freeze-thaw process of factor VIII-deficient plasma.
[0071] Table 9. Results of Freeze-Thaw Stability Test
[0072]
[0073]
[0074] Example 6 Long-term stability
[0075] Plasma lacking factor VIII in the experimental group and plasma from the control groups 1-2 were freeze-dried and stored at +2 to +8°C. Every 3 months, one vial was taken out and reconstituted with 1 mL of distilled water, while simultaneously reconstituted the commercially available reagent kit to the indicated volume. The detection method involved using Siemens original quality control plasma within the normal range (Control Plasma N) and plasma within the pathological range (Control Plasma P), with three repeated measurements. The mean of the results was calculated. Linear regression was performed on the results, and a two-tailed t-test was conducted to assess the significance of the slope b versus 0. The results are shown in Table 10. Table 10 shows that α = 0.05, ν = 12, and tα(ν) = 2.179. The p-values for the activity assay results of the reagent kit of this invention are all greater than 0.05, which fully demonstrates that the reagent kit of this invention is more stable than the commercially available reagent kit. The freeze-dried product of the reagent kit of this invention showed essentially unchanged activity values after 39 months of storage at +2 to +8°C, exhibiting good long-term stability, which is beneficial for commercial production. The results of the test kit of this invention and the control group 1-2 fully demonstrate that the presence of magnesium sulfate and polyvinylpyrrolidone in factor VIII-deficient plasma can effectively improve the stability of enzyme activity during the storage of factor VIII-deficient plasma.
[0076] Table 10 Long-term stability test results
[0077]
[0078]
[0079] Example 7: Applicability of the reagent kit of the present invention to mainstream fully automated coagulation analyzers on the market.
[0080] (1) Comparison with similar reagent kits from Siemens on the CS5100
[0081] One hundred clinical samples were randomly selected from inpatients and outpatients of Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine. Blood was mixed with 0.11 mol / L sodium citrate anticoagulant at a ratio of 9:1, centrifuged at 1500g for 15 minutes, and plasma was obtained. The clinical samples were measured on a CS5100 using the kit obtained in Example 1 (experimental group) and the Siemens Factor VIII Activity Assay Kit (coagulation method), respectively. The correlation coefficient between the two kits was calculated, and linear regression was performed. The results showed that the correlation coefficient r = 0.99558 for the sample measurements on the CS5100, and the linear regression equation was y = 0.97823x + 0.23706. (See [link to relevant documentation]). Figure 1 .
[0082] According to the requirements of the Clinical Laboratory Standards Institute (CLSI) document (r > 0.975), the test data of the kit of this invention and the imported kit from Siemens, Germany, show good consistency.
[0083] (2) Comparison with similar reagent kits from Stago on STA-R Evolution
[0084] One hundred clinical samples were randomly selected from inpatients and outpatients of Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine. Blood was mixed with 0.11 mol / L sodium citrate anticoagulant at a ratio of 9:1, centrifuged at 1500g for 15 minutes, and plasma was obtained. The clinical samples were measured on a STA-R Evolution using the kit obtained in Example 1 (experimental group) and the Statop Factor VIII Activity Assay Kit (coagulation method), respectively. The correlation coefficient between the two kits was calculated, and linear regression was performed. The results showed that the correlation coefficient r = 0.99045 between the two kits on the STA-R Evolution, and the linear regression equation was y = 1.00005x + 0.42819. (See [link to STA-R Evolution kit]). Figure 2 .
[0085] According to the requirements of the Clinical Laboratory Standards Institute (CLSI) document (r > 0.975), the test data of the kit of this invention and the kit of Stago Corporation show good consistency.
[0086] (3) Comparison with similar reagent kits from IL on ACL TOP750
[0087] One hundred clinical samples were randomly selected from inpatients and outpatients of Longhua Hospital affiliated with Shanghai University of Traditional Chinese Medicine. Blood was mixed with 0.11 mol / L sodium citrate anticoagulant at a ratio of 9:1, centrifuged at 1500g for 15 minutes, and plasma was obtained. The clinical samples were measured using the kit of this invention (experimental group) obtained in Example 1 and the Factor VIII deficient plasma kit for IL on an ACL TOP750, respectively. The correlation coefficient between the two kits was calculated, and linear regression was performed. The results showed that the correlation coefficient r = 0.99045 for the sample measurements on the ACL TOP750, and the linear regression equation was y = 1.00005x + 0.42819. (See [link to relevant documentation]). Figure 3 .
[0088] According to the requirements of the Clinical Laboratory Standards Institute (CLSI) document (r > 0.975), the detection data of the kit of this invention and the kit of IL Corporation show good consistency.
[0089] In summary, the kit of this invention can be used on different coagulation analyzers, thus having a wider range of applications.
[0090] The above are merely preferred embodiments of the present invention. It should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A protective agent characterized in that, The protective agent is composed of water, 10-80 mM HEPES buffer, 1-10 mM magnesium sulfate, 0.1-1 g / L polyvinylpyrrolidone, 10-50 g / L histidine, 10-50 g / L trehalose and 0.001%-0.005% (w / v) ciprofloxacin, and the pH value of the protective agent is 7.
5.
2. The protective agent according to claim 1, characterized in that, The protective agent consists of water, 50 mM HEPES buffer, 5 mM magnesium sulfate, 0.5 g / L polyvinylpyrrolidone, 25 g / L histidine, 25 g / L trehalose and 0.002% (w / v) ciprofloxacin, and the pH of the protective agent is 7.
5.
3. The use of the protective agent according to claim 1 or 2 in the preparation of coagulation factor VIII-deficient plasma or in the preparation of a kit containing coagulation factor VIII-deficient plasma.
4. Plasma deficient in Factor VIII, or a kit comprising plasma deficient in Factor VIII, characterized in that, The factor VIII deficiency plasma comprises human factor VIII deficiency plasma and the protective agent as described in claim 1 or 2.
5. The use of factor VIII deficient plasma as described in claim 4 in the preparation of coagulation factor VIII activity detection reagents or kits.
Citation Information
Patent Citations
High-purity prothrombin complex product freeze-drying stabilizer
CN102441172A
Activated partial thromboplastin time detection reagent and detection method
CN108226539A
Thrombin time quality control product as well as preparation method and application thereof
CN115494247A
Methods of production and use of liquid formulations of plasma proteins
US5925738A
